chartexchange

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

GlobeNewswire Inc. | Sep 24, 2026 6:00 AM EDT

Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise

Read original article